Wednesday, July 8, 2026

pharma · Colorectal Cancer Screening · Screening for Colon Cancer · MRKR

ME Therapeutics

ME Therapeutics clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Vancouver, British Columbia, CA HQ
2018 Founded
4 Employees
Public company Type
MRKR · NYSE Ticker
Company details
Status
Public
HQ
Vancouver, British Columbia, CA
Founded
2018
Employees
4
Programs
13
Drugs
10
Patents
27
Intelligence · Clinical Programs

ME Therapeutics projects

4 ClinicalTrials.gov programs sponsored by ME Therapeutics.

ME Therapeutics has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. HER-2/neu peptide vaccine

    Marker Therapeutics

    HER2-positive Breast Cancer

    phase 1 mab completed

    1 trial
  2. MT-401-OTS

    Marker Therapeutics

    Acute Myeloid Leukemia, in Relapse

    phase 1 small molecule active

    1 trial
  3. MT-601

    Marker Therapeutics

    Non-Hodgkin Lymphoma, Adult

    phase 1 small molecule active

    1 trial
  4. MT-601 dose 200 million cells

    Marker Therapeutics

    Pancreas Cancer

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does ME Therapeutics have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.